New Treatment Against Covid-19

The Institut Pasteur de Lille (France) will implement the protocol to perform clinical tests of a promising treatment against Covid-19. An authorization from the National Agency for the Safety of Medicines and Health Products (ANSM) which nevertheless comes eight months after the announcement of the discovery of this molecule by the teams of researchers.

On September 29, the Institut Pasteur de Lille confirmed to 20 Minutes have found an effective molecule against Covid-19.

It remains to conduct a clinical trial to definitively validate the antiviral activity of this molecule”, then underlined a member of the research team. This molecule had already received marketing authorization from the ANSM under the name Clofoctol for a pathology other than Covid-19. It was therefore a question of “repositioning” it as a Covid-19 treatment since “the in vitro tests have shown the effectiveness of this molecule in inhibiting the replication of the virus”, assures the Institute.

The file presented by Pasteur was validated by the Committee for the Protection of Persons (CPP) and, on Thursday, it also received the approval of the ANSM.

The clinical trial to test this experimental treatment in the early management of Covid patients, double-blind against placebo” will be able to start, “all the logistics are ready”, continues at Pasteur Lille. This test will take place in Hauts-de-France, in five centers. To be able to be included in this clinical trial, it is necessary to have made “a recent positive test, to be more than 50 years old, to have at least one symptom and not to have been vaccinated”.

If the administration of the drug will be done in the different centers, the patients will not be hospitalized. The follow-up will be provided at home thanks to the collaboration of general practitioners.

Source: https://news.in-24.com/

New Coronavirus Treatment: Patients Are Two To Three Times More Likely To Recover

The preliminary results of a clinical trial suggest a new treatment for Covid-19 reduces the number of patients needing intensive care, according to the UK company that developed it.  The treatment from Southampton-based biotech Synairgen uses a protein called interferon beta which the body produces when it gets a viral infection. The protein is inhaled directly into the lungs of patients with coronavirus, using a nebuliser, in the hope that it will stimulate an immune response.

The initial findings suggest the treatment cut the odds of a Covid-19 patient in hospital developing severe disease – such as requiring ventilation – by 79%Patients were two to three times more likely to recover to the point where everyday activities were not compromised by their illness, Synairgen claims.

It said the trial also indicated “very significant reductions in breathlessness among patients who received the treatment. In addition, the average time patients spent in hospital is said to have been reduced by a third, for those receiving the new drug – down from an average of nine days to six days.

Source: https://www.synairgen.com/
AND
www.bbc.com